Meet Moin Din, Senior Recruitment Consultant at CK Clinical. Moin specialises in recruiting for Medics and senior level appointments within the Pharmaceutical, CRO, Biotechnology and Healthcare industries.
Moin covers all permanent, interim and contract recruitment within CK Clinical’s Medic Recruitment function. To find out more, please watch Moin’s short video below:
Looking for a Medic job in the Pharmaceutical Industry?
Recruiter reported that Amgen are investing £123 million in their site n Ireland, which will create up to 100 new jobs.
The US biotechnology company’s expansion program in Dun Laoghaire will create 100 jobs and also 350 construction jobs in the construction period.
The expansion includes the construction of an 11,700 sq-metre building extension, a new production plant, an expanded warehouse and the major refurbishment of its existing buildings.
Martin VanTrieste, senior vice-president of Quality at Amgen said ““We are very pleased to expand our investment in Ireland…….As we expand internationally, Dun Laoghaire will enhance our global production capability, ensuring continuity of supply of Amgen medicines for seriously ill patients worldwide.
Priya Mukherjee at CK Clinical is currently recruiting for a Clinical Data Manager to join a leading Pharmaceutical company based in London.
As Clinical Data Manager you will be working in close partnership with Offshore Data Management Staff performing CRF/eCRF data validation to ensure data integrity and quality. You will also manage data queries manual or automated and maintenance of CRF according to data query replies which may involve interpretation and decision making as to appropriate course of action.
Further responsibilities of this Clinical Data Manager job include:
To run, review, action and resolve listings of errors/inconsistencies identified by validation checks;
T validate and reconcile vendor data as needed; Reconcile the Serious Adverse Events in the CRF/eCRF and Clinical Database with the Central Safety Serious Adverse Events Database;
To participate in the QC review of study data prior to study release;
To assist with the review and evaluation of protocol against CRF;
To report findings to senior staff to assure consistency and accuracy;
To assist in the development of data validation specifications;
To effectively communicate with colleagues and customers to maintain a consistent approach in handling the work;
The ideal candidate for this Clinical Data Manager job will have a BSc (or equivalent) in a scientific discipline along with proven experience of working as a Data Manager for either a Pharmaceutical, Biotechnology or Clinical Research Organisation. You will also have experience of:
Oncology data management
Local and central lad validation
How to apply:
Click here to apply for this Clinical Data Manager position, or contact Priya Mukherjee at CK Clinical on +44(0)1438 870028 or email firstname.lastname@example.org. Please quote reference CL23436 in all correspondence.
The trial, which has been running since 2007, is evaluating the effectiveness of the breast cancer drug Tyverb in four different combinations, following surgery. The patients in the trial receive either Tyverb, Roche’s established drug Herceptin, Herceptin followed by Tyverb or both drugs.
An interim report has indicated that the patients only receiving Tyverb are not demonstrating any improvement compared to Herceptin, so that arm of the trial has been discontinued. Those who are halting their treatment are to discuss other options with trial physicians. 8,400 patients are taking part in the study, and the remaining three trials are to continue as normal.
The half a billion pound investment to build a new biopharmaceutical plant is to be built in one of five places, with the Evening Mail reporting on a site near Ulverston’s attempts to gain the 300 potential jobs. The local council has guaranteed GSK planning permission on an existing plant, and has also dropped the planning fees which could have cost nearly £100,000, as incentives.
Councillor Graham Vincent has voiced his approval of the scheme, believing his council needs to fight for the “incredible” investment potential. The site would be at the cutting edge of the biopharmaceutical industry and set itself apart from traditional chemical manufacturing. However, the council is not being naïve about the race for the investment, determined to do all it can to secure the development which could bring in upwards of £10 million annually for whichever council is chosen. Barnard’s Castle in Durham, as well as plants in Montrose and Irvine in Scotland, are also being considered.
ICON, already global clinical development partner to Bristol Myers-Squibb, have added to the agreement by announcing a preferred provider agreement with BMS in early-phase studies, reports inpharm.com.
The agreement includes full service clinical pharmacology and exploratory clinical studies, based in Manchester in the UK and elsewhere around the world. ICON will also be responsible for all the scientific support services during the trials, such as biostatistics and clinical monitoring, amongst a variety of others.
Dr Mario Rocci, president of ICON Development Solutions, is looking forward to “demonstrating the same values and efficiencies to BMS’s early phase clinical programmes” as they do with phase II-IV studies. Under this new agreement, ICON expects to be able to report “significant cost savings and productivity” by putting it’s global network to use.
The £1.25 million investment is to be put into the start up in return for a 25% equity stake, alongside £10 million from other investors including SV Life Sciences. £400,000 is to be put into development data for hearing loss, patent applications and several ion channel modulated compounds.
As part of the agreement, GSK will be eligible to receive another 550,000 shares upon pre-determined milestones being achieved. Upon this, further investment will be made by the consortium of other investors which will reduce GSK’s stake to 13%.
It was concluded by the EU’s executive arm that the acquisition would not have a negative impact on competition in Europe. They stated, “The Commission’s examination has shown that the proposed transaction would not lead to significant combined market shares in the product categories where the parties’ activities overlap.
“In addition, the proposed transaction also does not raise concerns in the treatment of multiple sclerosis, where both parties are developing treatments. In all cases there will remain a sufficient number of other credible competitors.”
CK Clinical, the leading independent pharmaceutical recruitmentconsultancy are recruiting for a Statistical Programmer for a leading CRO based in Wales.
This Statistical Programmer role will involve taking responsibility for the statistical analysis and reporting of a number of phase I clinical trials, providing input into clinical study protocols, writing statistical analysis plans, performing statistical analyses and reporting of TFLs to internal management and to external clients.
The main responsibilities of this Statistical Programmer role will include:
Providing statistical input into the planning and development of clinical study protocols by creating/adapting the appropriate statistical requirements.
Being involved in the creation of statistical analysis plans including the designing of data listings, table and figure shells for external clients in liaison with project managers.
Providing clinical SAS programming support to projects according to specifications within the statistical analysis plan.
We are interested in applicants that hold an MSc in Statistics with proven experience as a Statistician working for either a Pharmaceutical/CRO/Biotechnology organisation. The ideal candidate for this Statistical Programmer role will also have substantial SAS programming expertise in the BASE, STAT and GRAPH modules of SAS (v9.1.3) to create listings, tables and figures. Working within Phases I & II is also desirable.
For more information, or to apply for this Statistical Programmer online now, please contact Priya at CK Clinical on +44 (0) 1438 870028 or email an updated copy of your CV to: email@example.com.